Zheng Quan Shi Bao Wang·2026-01-08 12:44Core Viewpoint - Baiyunshan Zhongyi Pharmaceutical's clinical research on Zishen Yutai Wan has achieved a significant breakthrough, with results published in the prestigious journal Nature Communications, marking the first clinical study on the application of traditional Chinese medicine in reproductive medicine in this journal [1] Group 1: Clinical Research Findings - The clinical study indicates that Zishen Yutai Wan significantly improves the live birth rate in women aged 35 and older undergoing fresh embryo transfer, with a relative increase of approximately 23% [1] - The study was designed as a multi-center, prospective, double-blind, placebo-controlled trial, involving 1,467 women aged 35-42 undergoing IVF/ICSI fresh embryo transfer across 12 top-tier hospitals [1] - The live birth rate in the Zishen Yutai Wan group reached 23.3%, significantly higher than the placebo group's 19.0%, with notable improvements in pregnancy test positivity rate, embryo implantation rate, and clinical pregnancy rate, without increasing the risk of adverse events for mothers and infants [1] Group 2: Research and Development Efforts - Baiyunshan Zhongyi Pharmaceutical has conducted pharmacological, toxicological, and multi-center evidence-based research projects on Zishen Yutai Wan, with the product and treatment protocols included in 16 textbooks and monographs [2] - The research outcomes have led to nearly 30 published SCI articles and 5 authorized invention patents, establishing Zishen Yutai Wan as a recommended medication for conditions such as threatened abortion, recurrent miscarriage, and infertility [2]